Sleep Apnea Worsens Non-Alcoholic Fatty Liver Disease in Obese Adolescents

Obstructive sleep apnea and intermittent nocturnal hypoxia are associated with NAFLD in both adults and children, according to a new report in the Journal of Hepatology

Amsterdam, August 5, 2016

Studies have shown that obstructive sleep apnea and low nighttime oxygen, which result in oxidative stress, are associated with the progression of non-alcoholic fatty liver disease (NAFLD) in adults. Investigators have now established that these factors may also be important triggers in the progression of pediatric NAFLD to non-alcoholic steatohepatitis (NASH), according to a new report in the Journal of Hepatology.

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of extra fat in liver cells in people who drink little or no alcohol. It is a disease of epidemic proportions that is increasing worldwide in both adults and children. It is estimated to affect up to 30% of the general population in Western countries and up to 9.6% of all children and 38% of obese children across a spectrum of disease, including isolated hepatic steatosis, non-alcoholic steatohepatitis (NASH, defined as steatosis, hepatocyte ballooning and inflammation), and cirrhosis. This parallels the growing incidence of obesity and type 2 diabetes, and is now considered to be the hepatic component of metabolic syndrome. Although isolated hepatic steatosis is considered a less aggressive form of NAFLD, patients with NASH can eventually progress to severe fibrosis and cirrhosis, with development of hepatocellular carcinoma in adults.

“There is emerging evidence that obesity-related obstructive sleep apnea (OSA) and intermittent nocturnal hypoxia are associated with NAFLD progression,” explained lead investigator Shikha Sundaram, MD, MSCI, of the Children's Hospital Colorado, University of Colorado School of Medicine. “According to recent reports, pediatric NAFLD patients with OSA/hypoxia have more advanced liver disease and fibrosis, supporting a role for OSA/hypoxia in the development of NASH. However, the mechanisms underlying this relationship have not yet been explained.”

Investigators studied 36 adolescents with NAFLD, along with 14 lean controls, to assess if oxidative stress induced by obstructive sleep apnea and low nighttime oxygen promoted the progression of pediatric NAFLD. Children cared for in the Children’s Hospital Colorado Pediatric Liver Center between June 2009 and January 2014 were eligible for this study if they had suspected NAFLD and were scheduled to undergo a clinically indicated liver biopsy. NAFLD patients had significantly raised aminotransferases (a marker of hepatocellular injury), inflammatory markers, and evidence of metabolic syndrome, compared to lean controls.

Patients underwent a standard multi-channel sleep study (polysomnogram), which was scored by a research trained technician and interpreted by a single sleep medicine physician, both of whom were blinded to the liver biopsy results.

Investigators found that patients with the most severe NAFLD experienced more severe sleep-disordered breathing and significantly higher apnea/hypopnea index scores compared to those with less severe NAFLD. Patients with OSA/hypoxia also had more severe fibrosis or scar tissue in their livers than those without OSA/hypoxia. They also found a clear correlation between severity of the indexes of oxidative stress both systemically and in the liver and the severity of the indexes used to evaluate OSA. The two populations of obese NAFLD adolescents did not differ for other relevant serum liver indexes and liver histology scores.

“These data show that sleep-disordered breathing is an important trigger of oxidative stress that promotes progression of pediatric NAFLD to NASH,” commented Dr. Sundaram. “We showed that obese adolescents with NAFLD who have OSA and low nighttime oxygen have significant scar tissue in their livers, and that NAFLD patients affected by OSA and low nighttime oxygen have a greater imbalance between the production of free radicals and their body’s ability to counteract their harmful effects than subjects without OSA and low oxygen.”

“Further proof of this hypothesis will require additional investigations to demonstrate prevention or reversal of NASH following effective therapy of OSA and low nighttime oxygen in obese patients. Nocturnal Continuous Positive Airway Pressure (CPAP) therapy may be a potential treatment by reducing intermittent nocturnal hypoxia-induced oxidative stress.”

In an accompanying editorial, Maurizio Parola, PhD, of the Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Clinical Pathology, University of Torino, Italy, and Pietro Vajro, MD, of the Department of Medicine and Surgery, Unit of Pediatrics, University of Salerno, Italy, commented that “the study by Sundaram and colleagues has merit and outlines a number of further relevant issues and perspectives. The investigators reported significant relationships between blood hematocrit (Hct) and NAFLD fibrosis stage, and anti-oxidant blood values, and between NAFLD and lipid peroxidation parameters. Their combined evaluation should help in deciding whether histological and polysomnographic evaluation are needed in order to recognize adolescent patients with more severe NAFLD and/or more severe OSA and hypoxia earlier.”

“We definitely need trials designed to investigate whether CPAP treatment may significantly affect NAFLD progression in this age range. The only randomized controlled trial was of relatively short duration, performed on adult patients with mild OSA/hypoxia and normal baseline transaminases, and apparently did not demonstrate any impact on steatosis, NASH or liver fibrosis,” they observed.

---

Notes for editors
The articles are "Nocturnal Hypoxia Induced Oxidative Stress Promotes Progression of Pediatric Non-Alcoholic Fatty Liver Disease," by Shikha Sundaram, Ann Halbower, Zhaoxing Pan, Kristen Robbins, Kelley Capocelli, Jelena Klawitter, Colin Shearn, and Ronald Sokol (doi: 10.1016/j.jhep.2016.04.010) and “Editorial: Nocturnal Hypoxia in Obese-Related Obstructive Sleep-Apnea as a Putative Trigger of Oxidative Stress in Pediatric NAFLD Progression,” by Maurizio Parola and Pietro Vajro, (doi: 10.1016/j.jhep.2016.05.042). They appear in Journal of Hepatology, volume 65, issue 3 (2016), published by Elsevier.

Full text of these articles is available to credentialed journalists upon request; contact Sybrand Boer Iwema at +31 20 485 2781 or hmsmedia@elsevier.com. Journalists wishing to interview the authors should contact Shikha S. Sundaram, at +1 720 777 6669 or Shikha.Sundaram@childrenscolorado.org. For questions concerning the Journal of Hepatology, please contact Editor-in-Chief Rajiv Jalan at hmsmedia@elsevier.com.

About the Journal of Hepatology
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports and letters to the Editor concerned with clinical and basic research in the field of hepatology.

About EASL
In the forty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Sybrand Boer Iwema
Publisher, Elsevier
+31 20 485 2781
hmsmedia@elsevier.com